Q3 Earnings Forecast for Zura Bio Issued By Leerink Partnrs

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2024 earnings per share estimates for shares of Zura Bio in a research note issued to investors on Monday, November 4th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.14) per share for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Zura Bio's Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($0.59) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.62) EPS.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02).

Other equities research analysts have also recently issued reports about the stock. Piper Sandler reaffirmed an "overweight" rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a research note on Friday, October 18th. Leerink Partners assumed coverage on Zura Bio in a research note on Monday. They set an "outperform" rating and a $15.00 target price for the company. Finally, HC Wainwright restated a "neutral" rating and issued a $5.00 price target on shares of Zura Bio in a research note on Monday, October 21st. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $16.75.

Zura Bio Stock Performance

NASDAQ ZURA traded up $0.19 on Wednesday, hitting $4.30. 447,543 shares of the stock were exchanged, compared to its average volume of 308,775. The business's fifty day moving average is $4.17 and its 200 day moving average is $4.09. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35.

Institutional Trading of Zura Bio

Several large investors have recently modified their holdings of ZURA. Affinity Asset Advisors LLC acquired a new stake in shares of Zura Bio during the 1st quarter worth approximately $1,157,000. Bank of New York Mellon Corp lifted its stake in Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock worth $165,000 after purchasing an additional 6,412 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after purchasing an additional 5,900 shares in the last quarter. Great Point Partners LLC increased its stake in shares of Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the last quarter. Finally, Armistice Capital LLC raised its holdings in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock worth $8,834,000 after buying an additional 876,000 shares in the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 22.10% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.